The Preclinical Oncology Models Market Size is valued at 1218.27 Million in 2022 and is predicted to reach 2678.15 Million by the year 2031 at a 9.3 % CAGR during the forecast period for 2023-2031.
The rise of immuno-oncology therapy such as T cell therapy, bispecific antibodies, immune checkpoint modulators, and personalized cancer vaccines compels the need for unique preclinical and translational service solution. Recently advances in Immuno-oncology industry with success of CAR-T Therapy boosted the R&D activities in the oncology industry which boost the demand for preclinical oncology models such as humanized models and syngeneic tumor models. The need for predictive approaches and robust preclinical models to minimize translational failures in immuno-oncology is very high. The factors such as early identification of predictive biomarkers, leveraging phenotypic features of models,and the need of rational design of combination therapies drive the growth of the oncology preclinical models market.
Market Segmentation
The global oncology preclinical models market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Syngeneic Models, Cell Lines Models, Orthotopic Tumor Models, and Others based on application type, the market is segmented into Neuroblastoma, Prostate Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Fibrosarcoma, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer and Others.
Competitive Landscape
Some Of The Key Players In The Preclinical Oncology Models Market:
- Aragen Bioscience,
- vivoPharm Pty. Ltd.
- Bioduro,
- Crown Bioscience Inc.,
- Charles River,
- Champion Oncology, Inc.,
- Envigo,
- GenOway S.A.,
- Hera BioLabs,
- MI Bioresearch Inc,
- Pharmatest Services,
- Taconic Biosciences, Inc.,
- The Jackson Laboratory
The Preclinical Oncology Models Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 1218.27 Million |
|
Revenue Forecast In 2031 |
USD 2678.15 Million |
|
Growth Rate CAGR |
CAGR of 9.3 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Aragen Bioscience, vivoPharm Pty. Ltd. Bioduro, Crown Bioscience Inc., Charles River, Champion Oncology, Inc., Envigo, GenOway S.A., Hera BioLabs, MI Bioresearch Inc, Pharmatest Services, Taconic Biosciences, Inc., and The Jackson Laboratory |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
